Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 15

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 15
---
 liabilities775,168 704,256 Commitments and contingencies (Note 19)Stockholders’ equity:  Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at December 31, 2024 and 2023— — Common stock, par value $0.001; 250,000,000 shares authorized; 47,077,844 shares issued and 46,240,604 shares outstanding at December 31, 2024 and 46,481,174 shares issued and outstanding at December 31, 202347 46 Treasury stock, at cost, 837,240 and zero shares at December 31, 2024 and 2023, respectively, inclusive of excise tax(25,121)— Additional paid-in capital1,009,435 976,633 Accumulated deficit(206,356)(106,796)Accumulated other comprehensive income343 247 Total stockholders’ equity778,348 870,130 Total liabilities and stockholders’ equity$1,553,516 $1,574,386 

See accompanying notes to consolidated financial statements.

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-5

PACIRA BIOSCIENCES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts) Year Ended December 31, 202420232022Revenues:   Net product sales$697,186 $672,245 $664,150 Royalty revenue3,780 2,733 2,673 Total revenues700,966 674,978 666,823 Operating expenses:   Cost of goods sold170,428 184,669 199,295 Research and development81,577 76,257 84,797 Selling, general and administrative294,099 269,441 254,516 Amortization of acquired intangible assets57,288 57,288 57,288 Goodwill impairment163,243 — — Contingent consideration gains, restructuring charges and other7,702 (352)10,903 Total operating expenses774,337 587,303 606,799 (Loss) income from operations(73,371)87,675 60,024 Other